Genmab reports 45.9% confirmed response rate for Rina-S in platinum-resistant ovarian cancer

Genmab reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial of its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 patients.

Detected & updated continuously · Source: Nebula